Roger, AlbertMalet, AlfonsMoreno, VictoriaParra, AntonioGutierrez, DiegoLleonart Bellfill, RamonMoreno, FranciscoValero, AntonioNavarro, BegoñaHinojosa, BelénJusticia, José L.2021-02-092021-02-092020-01-01https://hdl.handle.net/2445/173759Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus((R)) in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting.10 p.application/pdfengcc by-nc-nd (c) Roger et al., 2020http://creativecommons.org/licenses/by-nc-nd/3.0/es/ÀcarsRinitisMitesRhinitisinfo:eu-repo/semantics/article2021-02-08info:eu-repo/semantics/openAccess31910695